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Introduction
In 1981 de Bold et al. reported that the injection of atrial tissue extracts in rats induced natriuresis, 
a discovery that initiated a ﬂ  urry of research leading to the discovery of a new class of cardiac 
hormones, the natriuretic peptides.
1 These peptides represent the ﬁ  rst line of response of the heart 
to defend the body against a number of processes, especially plasma volume expansion. Since 
circulating concentrations of natriuretic peptides are elevated in heart failure (HF) and given that 
clinical parameters for the evaluation and management of HF have a poor sensitivity and speciﬁ  city, 
these peptides were a more than welcome addition to standard clinical evaluation, as a marker to 
identify HF. Nowadays, Brain Natriuretic Peptide (BNP) and its cleavage equivalent aminoterminal-
proBNP (NT-proBNP) have proven its clinical diagnostic but also prognostic value in HF, and have 
shown to be superior as a diagnostic parameter for HF when compared to chest X-ray and param-
eters of physical examination.
2–4 In this paper, we aim to discuss the background, the value, and of 
course the potential pitfalls encountered by clinicians using NT-proBNP testing in their daily 
clinical practice.
The ABC of The Natriuretic Peptides: It’s All in The Family
The family of natriuretic peptides consists of several tightly-related members: atrial natriuretic peptide, 
B-type (formerly ‘brain’) natriuretic peptide, C-type natriuretic peptide and dendroaspis natriuretic 
peptide.
5,6 Each of these peptides have the ability to induce natriuresis
7 and share a common 17-amino-
acid ring structure (Fig. 1).
Atrial natriuretic peptide (ANP) is primarily produced in both atria; production and release of
ANP is typically triggered by increased atrial-wall tension typically following an increase of intravas-
cular volume or pressure. The ventricles of normal adults produce only small amounts of ANP,
but this production is enhanced in the ventricular tissue of fetuses/neonates and in hypertrophied 
ventricles.
1,5,8
B-type natriuretic peptide (BNP), originally identiﬁ  ed in the porcine brain, is found wherever myocar-
dium is present, but is particularly concentrated in the cardiac ventricles. BNP and its cleavage equiv-
alent NT-proBNP have emerged as superior markers for left-ventricular dysfunction, because when 
cardiomyocytes are stretched, these peptides are rapidly expressed at gene level and immediately released 
into the circulation. Importantly and in contrast to ANP, these peptides are also more stable,
9,10 allowing 
for greater ease in their measurement. The similarities and differences between BNP and NT-proBNP 
will be discussed more into detail below.
C-type natriuretic peptide (CNP) has two forms, which are both products from a different cleavage 
process of a pro-CNP precursor. CNP predominates in the vascular endothelial cells, the central nervous 
system, the kidney and the pituitary gland. Plasma-concentration is low but tissue expression is high, 
suggesting a paracrine role for CNP.
11,12 Dendroaspis natriuretic peptide (DNP) was isolated in the 
venom of the Green Mamba. Although it has proven to induce natriuresis, it remains unclear whether 
it plays any role in the physiology of mammals.
6,13
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BNP and NT-proBNP:
Brothers in Arms?
When cardiomyocytes are stretched, as in cardiac 
chamber overﬁ  lling, the BNP gene is quickly up-
regulated, which leads to a rapid intracellular 
production of a 134 pre-pro-peptide. This pre-pro-
peptide is rapidly cleaved to a 108 pro-peptide, 
proBNP108. This proBNP108 is enzymatically 
cleaved immediately in a 1:1 ratio to yield BNP 
(32 amino acids) and NT-proBNP (76 amino acids) 
which are directly released into the circulation.
14 
(Fig. 2) Interestingly, not all the proBNP produced 
in the cardiomyocytes is cleft since intact 
proBNP108 is measured in the circulation as well.
15 
Figure 1. Structure of human cardiovascular natriuretic peptides: ANP, BNP and CNP.
Figure 2. Derivation of BNP and NT-proBNP from their common predecessor proBNP108.
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Schellenberger et al. also report the presence of 
small amounts of glycosylated proBNP in the 
circulation, which is typically of much larger 
molecular weight.
16 Athough proBNP108 is known 
to be detected by all BNP and NT-proBNP assays, 
whether glycosylated proBNP108 has any effect on 
conventional assays for natriuretic peptides is still 
not known.
While NT-proBNP is thought to be inert without 
any physiological function, BNP is biologically 
active and is responsible for several compensatory 
mechanisms in HF such as an increase of urine 
production and sodium excretion, a decrease of the 
aldosterone level, a lowering of the blood pressure 
and a lowering of the pulmonary capillary wedge 
pressure.
17,18 BNP in physiological concentrations 
has too little effect to restore euvolemia but BNP is 
studied as a potential therapeutic agent in HF.
19–22
Importantly, the clearance of the two peptides 
is different: BNP is cleared by several mecha-
nisms, including the kidneys, speciﬁ  c clearance 
receptor-mediated degradation (natruretic peptide 
receptor type C; NPR-C) and catalytic degradation 
via enzymes, especially neutral endopeptidase 
24.11,
23 but possibly also by other enzymes.
24 In 
contrast, NT-proBNP seems to be only renally 
cleared.
25,26 These differences in clearances are 
responsible for the fact that BNP has a lower 
absolute plasma concentration and a shorter 
biological half-life of 20 minutes. As well, due to 
ongoing effects of neutral endopeptidases, BNP 
degradation continues even after phlebotomy. The 
ramiﬁ  cations of these facts were recently illus-
trated by Mueller and colleagues who demon-
strated that after 2–4 months of storage in –20°C, 
less than 50% of BNP could be recovered in the 
plasma samples, while more than 90% of
NT-proBNP was still intact;
27 also a recent report 
demonstrates that measurable “BNP” is actually 
more likely a mixture of degraded BNP fragments, 
as highly-accurate gas chromatographic tech-
niques showed no intact BNP in specimens with 
high readings for the marker.
28 In contrast,
NT-proBNP is a more stable molecule (with a 
biologic half-life of 60–120 minutes) with conse-
quently absolute plasma concentrations of
NT-proBNP that are 3–4 times higher than BNP, 
and without any special conditions required for 
sampling. In addition, it should be noticed that 
there is cross reactivity for NT-proBNP assays 
with proBNP108, but not with other BNP frag-
ments.
Despite the potential differences and analytical 
concerns, recent head-to-head comparisons show 
that BNP correlates as well as NT-proBNP with 
clinical variables in patients with HF, indicating 
that most of the results of the BNP and NT-proBNP 
studies are generally transposable.
29–31
NT-proBNP: Diagnostic in Dyspnea
In the Emergency Department (ED), it is important 
to quickly diagnose the primary cause of acute 
dyspnea, since the success of most treatment 
therapies depends on the time-interval between 
presentation and treatment. Physicians therefore 
need a tool which is quickly available and 
adequately diagnoses or excludes HF. Although 
echocardiography can be performed quickly, it has 
to be carried out by an experienced person. Besides 
that, there is discussion what should be the echo-
cardiographic gold standard for the diagnosis of 
diastolic HF.
32,33
Smaller studies already had suggested that NT-
proBNP was such a beneﬁ  cial diagnostic tool in 
acute dyspnea.
31,34 However, the ProBNP Investi-
gation of Dyspnea in the Emergency Department 
(PRIDE) study was the landmark trial conﬁ  rming 
that NT-proBNP measurement was valuable for 
the evaluation of dyspnea, representing a superior 
predictor of acute HF when compared to clinical 
assessment alone.
35 This prospective, blinded trial 
of 600 dyspneic patients presenting to the ED, 
found that NT-proBNP concentrations were signif-
icantly higher in those with acute HF versus those 
without and demonstrated a close correlation to 
symptom severity. (Fig. 3) Besides, a subanalysis 
of this study also conﬁ  rmed that NT-proBNP is not 
only diagnostic in systolic HF, but is also diag-
nostic in diastolic HF.
36
Further insights to the value of NT-proBNP 
testing for the evaluation of acute dyspnea came 
from the International Collaborative Of NT-
proBNP (ICON) Study.
4 Brieﬂ  y, the ICON Study 
consists of 1256 patients suffering from acute 
dyspnea, who presented to the ED of 4 university 
hospitals in Maastricht, Barcelona, Christchurch, 
and Boston. In the ICON population, 720 patients 
were finally diagnosed with acute HF as the 
primary cause of their shortness of breath while in 
the other 536 patients other causes for acute 
dyspnea were diagnosed. From these data, the 
authors derived the following optimal strategy for 
the implementation of NT-proBNP in acute 
Biomarker Insights 2006:1146
Kimmenade and Januzzi
dyspnea: for the exclusion of acute HF, a general 
age-independent cut-point of 300 pg/mL should be 
used, while for diagnosis of HF, age-dependent 
cut-points were more useful than a single cut-point: 
namely NT-proBNP > 450 pg/ml for patients < 50 
years, > 900 pg/ml for patients in between 50 and 
75 years, and NT-proBNP > 1800 for patients > 75 
years. (Table 1)
This age-stratiﬁ  ed approach was superior to 
using a single NT-proBNP cut-point; both were 
equally sensitive and speciﬁ  c, but by stratifying 
age, the positive predictive value of the marker 
increased signiﬁ  cantly, speaking to the strong 
relationship between age and structural/functional 
physiologic changes with effects on natriuretic 
peptide values. Such an age-related effect on natri-
uretic peptides is by no means restricted to NT-
proBNP; recent data suggest age is the most potent 
variable leading to an elevated BNP value in the 
absence of acute HF, with a 30% increase in the 
likelihood for a “false positive” BNP per decade 
of age.
37 Accordingly, while a cut-point of 100 
pg/ml is optimal for excluding HF in middle-aged 
patients, a wide “grey zone” (a zone between ‘rule 
out’ and ‘rule in’ cut-points, where predictive value 
is low) exists for BNP, with 500 pg/ml as a cut-
point for including HF, and optimal BNP cut-points 
for younger or more elderly patients remain yet 
Figure 3. Median NT-proBNP concentrations as a function of dyspnea severity among 209 subjects with acute HF in the PRIDE study.
Table 1. Optimal NT-proBNP cut-points for the diagnosis or exclusion of acute HF among dyspneic patients.
Category Optimal  Sensitivity  Speciﬁ  city  PPV  NPV  Accuracy 
 cut-point
Conﬁ  rmatory (“rule in”) cut-points
<50 years (n = 183)  450  pg/ml 97% 93% 76%  99% 94%
50–75 years (n = 554)  900  pg/ml 89% 81% 82%  88% 85%
>75 years (n = 519)  1800  pg/ml 85% 72% 92%  55% 83%
Rule in, overall   87% 83% 86%  66% 85%
Exclusionary (“rule out”) cut-point
All patients (n = 1256)  300 pg/ml  99%  60%  77%  98%  83%
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unknown. This age-dependent cut-point strategy 
proposed from ICON offers other advantages. 
Importantly, this age stratiﬁ  cation narrows the 
“grey zone” considerably; this NT-proBNP cut-
point strategy enables the physician to diagnose or 
exclude HF in 84% of the patients, without taking 
any other clinical or technical parameter into 
account.
38 In contrast, for BNP testing, a single 
age-independent rule-in and and age-independent 
rule-out cut-point is advocated (i.e. BNP <100 
pg/ml for excluding HF and BNP >500 pg/ml for 
diagnosing HF) but this strategy only succeeds in 
adequately conﬁ  rming or rejecting the diagnosis 
of HF in 74% of the cases.
37 The diagnoses of 
patients with grey zone NT-proBNP concentrations 
but not suffering from acute HF in the ICON studye 
are listed in Table 2.
NT-proBNP: The Prognostic Peptide
Despite important improvements the last decade 
in the treatment of HF such as the introduction of 
beta-blockers or implantable deﬁ  brillators,
39,40 the 
prognosis of patients with HF is still poor, with a 
5 years survival of merely 50%.
41 Furthermore, 
while the life-time risk of developing HF is 1 out 
of 5,
42 paralleled by a substantial increase in costs 
for modern society,
43 an accurate tool for stratifying 
risk in HF is worthwhile, in order to intervene more 
substantially with the hope to reduce such risk, and 
secondarily reduce the burden on the health care 
system. The classical predictors of prognosis in 
HF that are used in clinical practice typically 
include symptom severity, maximal oxygen 
consumption and left ventricular ejection fraction 
(LVEF), together with classical risk markers such 
as diabetes, older age and male gender.
44–47
NT-proBNP has shown not only to be a powerful 
predictor of outcome in HF both on short term
48 
and one year time period,
49 it is even a better 
predictor than maximal oxygen consumption, 
LVEF, or any other risk markers.
4,50–52 Moreover, 
patients in whom NT-proBNP concentration 
decreases in reaction to therapy have a better prog-
nosis;
53 in an interesting pilot study including 69 
patients, NT-proBNP was a superior guide for 
therapy than the combination of classical clinical 
symptoms and signs.
54 Interestingly, the ICON 
study has shown that in 1256 patients with acute 
dyspnea, NT-proBNP was the best predictor of 
prognosis, regardless whether the patient was 
diagnosed with HF or not (Fig. 4) implying the 
importance of NT-proBNP for stratifying risk in 
dyspnea; the authors argue that in a dyspneic 
patient, there is no such thing as a “false positive” 
NT-proBNP, and elevations in a patient without 
acute HF should not be ignored.
NT-proBNP: Special Considerations
NT-proBNP and Valvular Heart
Disease
Valvular heart disease is a common cause of HF, 
either by leading to volume overload (e.g. mitral 
regurgitation) or by causing pressure overload
(e.g. aortic stenosis), and these relationships are 
frequently reﬂ  ected in changes of NT-proBNP 
values. Since the clinical tools typically utilized to 
time the moment of intervention for valve repair 
or replacement are frequently limited to clinical 
judgment, an objective measure to guide the timing 
for intervention would be welcome, particularly 
Table 2. Diagnoses in patients from the ICON studye with a “grey zone” NT-proBNP, not suffering from acute HF.
Diagnosis   Patients (n = 99)
Chronic Obstructive Pulmonary Disease/ Asthma  12%
Pneumonia/bronchitis  12%
Acute Coronary Syndrome / chest pain  12%
Arrhythmia/Bradycardia  8%
Lung cancer (including metastases)  5%
Anxiety Disorder  5%
Pulmonary Emboli  3%
Pulmonary hypertension  1%
Pericarditis  1%
Other*   21%
Unknown  19%
*Includes: anemia, cancer, gastrointestinal pathologies, sleep apnea, septic shock.
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since for instance recovery of LVEF or regression 
of LV mass is all but guaranteed after well-timed 
aortic valve replacement for aortic stenosis.
55 
Accordingly, the possible role of NT-proBNP in 
making the decision to operate upon these patients 
is of growing interest.
As an example, several studies have shown that 
NT-proBNP indeed correlates not only with onset 
and severity of symptoms but also with prognosis 
in aortic stenosis.
56–59 Gerber et al. studied 74 
patients with isolated aortic stenosis, and found 
that, after adjustment for age, sex, serum creatinine, 
aortic valve area and LVEF, that NT-proBNP 
concentrations were 1.74 times higher (1.12–2.69 
95% CI) for symptomatic than asymptomatic 
patients with aortic stenosis.
57 This is supported 
by the work of Weber and colleagues, who have 
also shown in their studies that NT-proBNP eleva-
tions were the earliest predictor of symptom onset, 
which is usually the moment when surgery is 
considered.
56,60 Also in mitral valvular disease, 
Figure 4. Kaplan-Meier curves demonstrating survival rates of all subjects in the ICON Study. ‘diagnostic’ means an NT-proBNP concentration 
above the rule-in cut-point for patients diagnosed with HF or below the rule-out cut-point in patients without HF.
several studies have indicated that the severity of 
valvular disease correlates with NT-proBNP 
concentrations, not only in mitral regurgitation,
61–63 
but also in mitral stenosis.
63–65
While most of these studies predict a promising 
role for NT-proBNP in valvular heart disease 
management, further research is warranted in order 
to establish the role of NT-proBNP in a decision 
algorithm for valvular heart disease.
NT-proBNP & Pulmonary Diseases
Patients with obstructive airway disease represent 
a particular challenge in the emergency department 
setting, as symptoms and signs of pulmonary 
disease may mimic (or mask) those of HF. Thus, 
the natriuretic peptides are a welcome advance for 
the correct identiﬁ  cation of HF in patients with 
prior lung disease. In a recent study, Tung and 
colleagues have shown in 216 patients with under-
lying chronic obstructive pulmonary disease 
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NT-proBNP concentrations (median 906 pg/mL; 
p <0.001).
67 Lastly, PAH can be caused by several 
mechanisms and is therefore sometimes considered 
as the next complication in systemic diseases such 
as systemic sclerosis, Mixed Connective Tissue 
Disease (MCTD), rheumatic arthritis etc. However, 
not all patients will develop PAH and it is difﬁ  cult 
to predict which patients will develop PH and 
which not. NT-proBNP might play a role as a 
screening tool. Indeed, a small study by Allonore 
et al. performed in 40 patients with systemic scle-
rosis suggests that NT-proBNP can be used as a 
screening tool for the early stage of PAH, when 
clinical symptoms are not present yet.
73
NT-proBNP and Obesity
One important population where a marker for HF 
would be incrementally useful is in the obese 
patient. These patients do often have complaints 
of dyspnea but clinical parameters (e.g. elevated 
jugular veins, lower extremity edema) and tech-
nical investigations (chest X-ray and echocardiog-
raphy) to make a diagnosis of HF are more difﬁ  cult 
to interpret. Especially since both the prevalence 
of HF and obesity are increasing in our modern 
society, a sensitive marker for HF in the obese 
population would be most welcome.
43,74
Surprisingly, HF patients with a higher body-
mass index (BMI) have a better prognosis than 
patients with a normal BMI, the so-called ‘Obesity-
paradox.’
75–78 What is even more interesting, is 
that subjects with a higher BMI also have lower 
BNP concentrations
79–81 which leads to speculation 
about the origin of this phenomena. For instance, 
it is known that BNP is also degraded by the NPR-C, 
which is abundantly expressed in adipocytes.
82 
Secondly, since it is more difﬁ  cult to diagnose HF 
in obese subjects, it is possible that some patients 
were wrongfully diagnosed with HF, which obvi-
ously leads to a better prognosis.
83,84
An important study in this perspective was 
performed by Krauser and colleagues.
85 In this 
ancillary analysis of the PRIDE study, it was 
demonstrated that both BNP and NT-proBNP 
correlated negatively with BMI. This rejects the 
hypothesis that lower concentrations of BNP or 
NT-proBNP in obese subjects are caused by 
increased clearance in obesity since NT-proBNP 
is not cleared by adipocytes. This was conﬁ  rmed 
by a small study that consecutively measured both 
NT-proBNP and BNP in subjects undergoing 
(COPD), that NT-proBNP was very useful for 
correctly identifying or excluding acute HF in this 
challenging patient population, superior to clinical 
judgment for this indication.
66 Importantly, in this 
analysis, NT-proBNP also detected previously 
unsuspected HF in 22 patients with prior obstruc-
tive airway disease, an important diagnosis to 
make, in order to reduce the potential hazard asso-
ciated with the dual diagnosis of pulmonary and 
cardiac insufﬁ  ciency.
An important consideration in patients with 
pulmonary disease is involvement of the right 
ventricle as a consequence of their pulmonary 
disease: since NT-proBNP is produced everywhere 
cardiomyocytes are present it is well known that 
cardiomyocytes in the right ventricle produce
NT-proBNP to a meaningful degree, particularly 
when stretched.
67 Therefore, although the concen-
trations are usually lower, NT-proBNP can be 
elevated in with patients with increased right 
ventricular pressures, such as in pulmonary embo-
lism (PE) or pulmonary arterial hypertension 
(PAH).
38,68 In patients with PE, echocardiographic 
studies have conﬁ  rmed that NT-proBNP concen-
trations correlate with echocardiographic and 
invasive measured parameters of right ventricular 
dysfunction.
68–70 Also, Kucher et al. have shown 
that elevated concentrations of NT-proBNP corre-
late with adverse clinical outcome in patients with 
PE,
71 which makes NT-proBNP not only a 
predictor of prognosis in these patients, but also 
a potential tool in therapy decision making (i.e. 
which patient should receive thrombolytic 
therapy).
In addition to acute right ventricular overload, 
NT-proBNP concentrations are also elevated in 
chronic PAH. Fijalkowska and colleagues demon-
strated that NT-proBNP concentrations were not 
only increased in patients suffering from PAH, but 
also predicted 3-year death. Importantly, a high 
long-term mortality rate (61%) was observed in 
patients in whom plasma NT-proBNP levels 
increased by at least 50% during the follow-up 
period, while the mortality rate was signiﬁ  cantly 
lower among other patients (12%; p< 0.001).
72
An interesting study was performed by Goetze 
et al. in a population of patients evaluated for lung 
transplantation. While the patients with terminal 
parenchymal pulmonary diseases and normal 
LVEF had normal NT-proBNP concentrations (i.e. 
median 22 pg/mL; all below 300 pg/mL), patients 
with primary PAH had significantly higher
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bariatric surgery. Following weight-loss surgery, 
postoperative BMI decreased dramatically in the 
study subjects, with parallel rise in both NT-
proBNP and BNP over time.
86 Importantly, BNP 
and NT-proBNP production in obese subjects is 
suppressed in the face of higher levels of ventric-
ular wall stress than in non-obese patients. Thus, 
the lower values of both peptides do not reﬂ  ect the 
obesity paradox in terms of prognosis, rather a 
derangement of neurohormonal regulation in obese 
HF patients.
The obvious ramiﬁ  cations of these data include 
this possibility of an obesity-related neurohor-
monal ‘suppression’ effect, such that the most 
obese patients may have a ‘handicap’ in their 
ability to secrete natriuretic peptides, and as such 
might be rendered more susceptible to hyperten-
sion, volume retention, and perhaps HF. As well, 
the interpretation of both BNP and NT-proBNP 
may be hindered by higher BMI; whether it inter-
feres with the prognostic value of the markers 
remained unclear. However, recent data from the 
ICON study group have shown that despite a 
decreased production of NT-proBNP in obese 
subjects, NT-proBNP keeps its diagnostic capa-
bilities across all BMI categories. (Antoni Bayes-
Genis, in press).
NT-proBNP and Renal Function:
Is the clearance clear?
Despite all the recent experience with NT-proBNP 
testing, there is still some debate how to interpret 
NT-proBNP concentrations in patients with renal 
impairment, since there is a inverse correlation 
between NT-proBNP and glomerular ﬁ  ltration rate 
(GFR).
87 Nevertheless, one should remember that 
there is a very tight relationship between cardiac 
and renal function. Indeed, the vast majority of 
patients with end stage renal disease (ESRD) have 
some degree of structural heart disease as well as 
plasma expansion related to decreased ﬁ  ltration. 
Conversely, the majority of the patients with HF 
have decreased renal function and risk factors for 
progressive renal disease.
88,89 Therefore, a strong 
inter-relationship between NT-proBNP concentra-
tions and parameters of renal function is in fact to 
be expected. This was conﬁ  rmed by two studies 
examining the role of NT-proBNP testing patients 
with renal impairment;
90,91 the germane question, 
however, is whether such a relationship will impair 
the utility of NT-proBNP testing in renal disease, 
and in these studies, NT-proBNP testing retained 
strong diagnostic and prognostic value even in the 
presence of renal impairment.
Considering the effects on renal disease and 
natriuretic peptides, certain very important 
concepts must be kept in mind. First, it is presumed 
that although steric and electrostatic factors also 
play a role in glomerular ﬁ  ltration, all molecules 
weighing less than 50 kDa should pass the glom-
erulus freely.
92 Since both BNP (3.5 kDa) and 
NT-proBNP (8.5 kDa) weigh signiﬁ  cantly less, 
ﬁ  ltration in the glomerulus cannot limit the clear-
ance of both natriuretic peptides in patients with 
moderate renal impairment. Also, since renal 
impairment in HF mostly depends on decreased 
renal blood ﬂ  ow rather than a decrease in ﬁ  ltration 
in the glomeruli,
93 it does not seem likely that the 
renal clearance of NT-proBNP is more hampered 
in renal impairment than the renal clearance of 
BNP. This also conﬁ  rmed by the renal clearance 
studies of BNP and NT-proBNP in several popula-
tion with moderate renal impairment.
94–96 In
addition, Tsutamoto and colleagues compared
NT-proBNP and BNP production with serum 
concentrations by sampling in the aortic root and 
the coronary sinus, and they found that there was 
no decrease in clearance until GFR was <40 ml/min. 
Although there is a higher NT-proBNP/BNP ratio 
described in patients with renal impairment,
97 one 
should bear in mind that BNP is also degraded by 
neutral endopeptidase 24.11 and the NPR-C 
receptor, which are both up-regulated in patients 
with renal impairment.
98,99
Importantly, while observational analyses 
regarding the effects of renal disease on natriuretic 
peptide values are important, the real matter at 
hand is optimal application of these markers for 
clinical use, and the available data suggest that 
when used at optimal cut-points, NT-proBNP is 
powerfully diagnostic and prognostic in patients 
with renal disease and dyspnea.
4,90 Indeed, when 
examining the available literature regarding BNP 
testing in renal disease in comparable popula-
tions,
100 it is hard to ﬁ  nd much of a difference 
between NT-proBNP and BNP testing in renal 
disease: both are affected, but both are valuable 
in these patients. Lastly, and very importantly 
emphasizing the importance of NT-proBNP in 
renal disease, the ICON study has also shown that 
both NT-proBNP and GFR are independent and 
additive predictors of prognosis in patients with 
HF.
101 In this sub-study, all 720 patients in ICON 
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Figure 5. Survival curves of HF subjects in ICON as a function of GFR and NT-proBNP concentration on admission (log-rank p<0.001).
diagnosed with HF were dichotomised according 
to median NT-proBNP concentration (4647 pg/mL) 
and according to presence or absence of
National Kidney Foundation “moderate or more” 
renal impairment (i.e. GFR<60 ml/min/1.73m²). 
While both NT-proBNP > 4647 pg/ml and GFR <60 
ml/min/1.73m² were independent predictors
of outcome (OR 2.67; 95% CI = 1.58–4.51 vs. 
OR 2.03; 95% CI = 1.18–3.49), the combination 
of a GFR<60ml/min/1.73m² with a NT-proBNP 
>4647 pg/ml was the best predictor of 60 day 
mortality (OR 3.46; 95% CI = 2.13–5.63). Among 
subjects with a NT-proBNP above the median, 
those with a GFR <60 ml/min/1.73m² had the 
worst prognosis while in subjects with a NT-
proBNP below the median, prognosis was not 
inﬂ  uenced impaired renal function at presenta-
tion. (Fig. 4) These results reject the assertion that 
NT-proBNP is not useful in renal disease, and in 
fact is strongly prognostic in the presence of 
impaired renal function.
NT-proBNP Testing in Ischemic
Heart Disease
Since in coronary ischemia (including both stable 
and unstable angina as well as acute myocardial 
infarction [MI]), myocardial wall stress increases, 
and variable reductions in LVEF may also occur, 
the possible role of NT-proBNP testing for evalu-
ation of ischemic heart disease has also been 
studied.
102,103 Seminal studies found indeed that 
NT-proBNP was a potential useful diagnostic and 
prognostic marker in MI.
104,105 Jernberg and 
colleagues also found in 775 patients admitted for 
acute chest pain without ST elevations that the 
patients in the 2nd, 3rd, and 4th quartile had a rela-
tive risk of subsequent death of 4.2, 10.7 and 26.6 
when compared to the lowest quartile.
106 Several 
studies have conﬁ  rmed that NT-proBNP is an 
independent predictor of mortality in patients 
suffering from an acute coronary syndrome (ACS) 
and moreover, even a stronger predictor for 
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mortality than troponin testing in this setting, 
regardless of any signs of HF.
105,107–110
These findings did not perfectly fit in the 
concept that NT-proBNP is merely a marker of 
acute myocardial stretch and suggest another 
mechanism. Firstly, NT-proBNP is associated with 
older age, hypertension, renal impairment, diabetes 
mellitus and pre-existent left ventricular dysfunc-
tion, which are also predictors of worse outcome. 
It might therefore be that NT-proBNP results “sum” 
up all these parameters, and represent a “ﬁ  nal 
common pathway” marker for prognosis. However, 
when corrected for these factors in multivariate 
analysis, NT-proBNP remains an independent 
predictor.
108 Secondly, other studies found eleva-
tions of BNP correlate with the size of ischemic 
myocardium, which is not necessarily stretch 
related;
111,112 as well, recent studies from the stress 
testing literature show unequivocal evidence for 
elevations in both NT-proBNP and BNP in patients 
with ischemia but with normal LV function.
113,114 
Finally, Goetze et al. found in vitro, that the secre-
tion of NT-proBNP in ischemia is mediated by a 
different pathway, triggered by hypoxia rather than 
myocardial stretch.
115,116 Accordingly, in addition 
to valuable risk stratiﬁ  cation in identifying those 
with an ACS on top of a dysfunctional ventricle, 
NT-proBNP levels may also reflect degree
and extent of myocardial ischemia. The role of 
NT-proBNP for routine inclusion in evaluation of 
chest pain is now underway.
Conclusions
NT-proBNP has now become an established marker 
in modern medicine, thanks to the broad array of 
data supporting its role in a number of disease 
states, most notably being HF. The results of
NT-proBNP testing are quickly available and have 
a high diagnostic value, even superior to single 
clinical parameters and chest X-ray. This diag-
nostic accuracy remains also in the presence of 
moderate renal impairment, underlying pulmonary 
disease or obesity. Besides its high diagnostic 
value, it is more important to realize that
NT-proBNP is also a most strong predictor of 
prognosis, not only in HF, but also in valvular heart 
diseases, pulmonary hypertension, and ACS. Thus, 
while troponins are necrosis markers and could be 
considered ‘the epitaph’ of the cardiomyocyte, 
NT-proBNP should be considered an ‘S.O.S. 
signal,’ which indicates that the cardiomyocyte is 
distress and some kind of intervention is needed.
The future of NT-proBNP testing is bright: at 
present numerous studies are examining the role 
of NT-proBNP testing for “screening” of appar-
ently well patients in primary are offices for 
incipient HF, while the role of NT-proBNP testing 
for the monitoring and titration of outpatient HF 
therapy is also under close examination.
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